Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges
Sander Lefere, Lindsey Devisscher, Frank Tacke
Abstract
KEYWORDS: Nonalcoholic steatohepatitisliver fibrosispharmacotherapyhepatocellular carcinomacenicrivirocNAFLDmacrophageCCR2 inhibitionCCR5 inhibition
Topics & Concepts
Nonalcoholic steatohepatitisSteatohepatitisFibrosisMedicineNonalcoholic fatty liver diseaseInternal medicineFatty liverDiseaseLiver Disease Diagnosis and TreatmentLiver physiology and pathologyHepatitis B Virus Studies